WHIPPANY, N.J., March 5, 2015 /PRNewswire/ -- Bayer HealthCare announced today that it has contributed one million dollars to the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) to support CancerLinQ™, a cutting edge health information technology platform designed to unlock vast quantities of information about the experiences of people living with cancer.
"Bayer is proud to join ASCO and the Conquer Cancer Foundation in their efforts to leverage Big Data to help people whose lives have been affected by cancer," said Svetlana Kobina, MD, PhD, Head of Global Medical Affairs, Oncology, Bayer HealthCare. "CancerLinQ is exciting in its potential to transform the future of cancer care through its ability to generate greater insights about patients living with cancer. This information can potentially help capture valuable data about quality of life during drug development."
The CancerLinQ system will provide insights needed to help increase understanding of the needs of cancer patients and their caregivers. The insights collected will ultimately contribute to high-quality, personalized cancer care for every patient.
"We are grateful for Bayer HealthCare's support of CancerLinQ, which aims to rapidly improve the overall quality of cancer care," said ASCO President Peter Paul Yu, MD, FACP, FASCO. "Instead of learning from only the three percent of cancer patients who participate in clinical trials, CancerLinQ will allow oncologists to learn from almost every patient."
For additional information about CancerLinQ, please visit http://CancerLinQ.org.
Bayer has a long-standing commitment to ASCO and the Conquer Cancer Foundation's mission of seeking advances in the prevention and treatment of cancer.
About Oncology at Bayer
Bayer is committed to delivering Science for a Better Life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company's approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.
About Bayer HealthCare Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Medical Care, and Pharmaceuticals divisions. As a specialty pharmaceutical company, Bayer HealthCare Pharmaceuticals Inc. provides products for General Medicine, Hematology, Neurology, Oncology and Women's Healthcare. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.
© 2015 Bayer HealthCare Pharmaceuticals Inc.
BAYER and the Bayer Cross are registered trademarks of Bayer.
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Intended for U.S. Media Only
SOURCE Bayer HealthCare